• Marie Hudson, Russell Steele, Suzanne Taillefer, Murray Baron, and Canadian Scleroderma Research.
• Sir Mortimer B. Davis Jewish General Hospital and McGill University, Montreal, Quebec, Canada. marie.hudson@mcgill.ca
• Arthritis Rheum. 2008 Feb 15; 59 (2): 270-8.

ObjectiveTo determine the validity of the World Health Organization Disability Assessment Schedule II (WHODAS II) in systemic sclerosis (SSc).MethodsPatients enrolled in the Canadian Scleroderma Research Group registry participated in a standardized evaluation and completed the WHODAS II. Criterion validity was assessed by comparing the WHODAS II with the Medical Outcomes Study Short Form 36 (SF-36), construct validity was assessed by examining how it relates to common measures of outcome in SSc, and discriminative validity was assessed by examining how it distinguishes patients with more severe disease from those with less severe disease.ResultsA total of 402 patients with SSc were included (mean +/- SD age 55 +/- 13 years, 87% women, mean +/- SD disease duration 11 +/- 9 years). The mean +/- SD WHODAS II score was 24.6 +/- 17.4, and the greatest impairments were in life activities and mobility. There were moderate to good correlations between the WHODAS II and the SF-36 Physical Component Summary score (r = -0.44), the SF-36 Mental Component Summary score (r = -0.41), and measures of function (r = 0.54), depression (r = 0.44), pain (r = 0.40), and fatigue (r = -0.49, P < 0.0001 for all). The WHODAS II was able to consistently distinguish patients with milder disease from those with more severe disease.ConclusionThe WHODAS II had good psychometric properties in patients with SSc and should be considered a valid measure of health-related quality of life in SSc.

16 keywords...

hide…